All In Biotech

NDA 208147 · Tris Pharma INC

Dyanavel Xr

Amphetamine, Amphetamine Aspartate/Dextroamphetamine Sulfate · Oral · Central Nervous System Stimulant

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 19, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

392

60 Phase 3, 36 recruiting

FAERS reports

6,459

5,279 serious, 3,009 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout DYANAVEL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) , Drug Abuse and Dependence (9.2) ] . WARNING: ABUSE, MISUSE,...

What it is approved for

From the label in effect Feb 24, 2026.

DYANAVEL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14) ]. Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. DYANAVEL XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older ( 1 ) Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ).

Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DYANAVEL XR · AMPHETAMINE 2MG/ML; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE EQ 0.5MG BASE/ML · SUSPENSION, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amphetamine" as an intervention, any sponsor and status, largest first.

All 392 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents1,624
  • drug abuse1,305
  • completed suicide666
  • overdose414
  • death355
  • cardiac arrest282
  • cardio-respiratory arrest266
  • drug ineffective266
  • off label use218
  • respiratory arrest216
  • fatigue191
  • drug dependence188

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200512
200613
200715
200816
20091
20107
201142
201236
2013227
2014264
2015394
2016232
2017299
2018464
2019524
2020498
2021437
2022481
2023539
2024709
2025784
2026448

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dyanavel XR (Amphetamine)

2024 spending

$717K

Beneficiaries

367

1,567 claims

Per beneficiary

$1,954

$13.81 per unit

View as table
YearSpending
2020$30,829
2021$38,327
2022$84,116
2023$482,764
2024$716,976

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,104 on PubMed

Sponsor: Tris Pharma INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.